Sanofi announces return of Auvi-Q to kaleo

Sanofi made an announcement this week to confirm that its license and development agreement with kaleo will expire later this year.

Kaleo was previously known as Intelliject Inc. and is credited with having developed Auvi-Q, which is an epinephrine injection used in the treatment of allergic reactions that may be life-threatening.

When the agreement officially expires, all United States and Canadian rights will return to kaleo. Discussions are currently under way between Sanofi and kaleo on the terms of the expiration of the agreement and to devise a transition plan. Kaleo has said that it will appraise options to put Auvi-Q back on the market.

Sanofi’s decision to return the rights of Auvi-Q back to kaleo aligns with its strategy to center its attention on critical therapeutic areas. This will impact all five of its business units around the world, including Diabetes & Cardiovascular, General Medicines & Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial. The return and reimbursement of last year's U.S. voluntary nationwide recall of Auvi-Q will be completed by Sanofi.